newsfilter
← Latest News
Business Wire·

Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer

Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ:FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead